Estudios
I+D+I
Institución
Internacional
Vida Universitaria
Atlantis Institut des Sciences Fictives
Recherche
Soumettre
Personnaliser
Vos alertes
Vos paniers
Vos recherches
Aide
EN
/
ES
Accueil
>
articulos
>
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial
> Accès aux Fichiers
Statistiques d'utilisation
Graphiques
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial
-
Gavilá, J.
et al
- ART-2019-110391
Main
fichier(s):
texto_completo
version 1
texto_completo.jpg (icon)
[74.65 KB]
19 fév 2019, 12:36
Versión publicada
texto_completo.pdf
[729.13 KB]
19 fév 2019, 12:36
Versión publicada